Summary
Proteins of the Bcl-2 family as well as p53 are important regulators of apoptosis. Alterations in the expression of these proteins can contribute to the formation of cancer, as well as influence tumour response to chemo- and radiotherapy. We used antibodies specific for the human Bcl-2, Mcl-1, Bax, Bak and p53 proteins to examine the expression of these apoptosis-regulating genes in 49 archival specimens of patients with radically resected non-small-cell lung cancer (NSCLC). Tumour cells containing immunostaining for the antiapoptotic proteins Bcl-2 and Mcl-1 were present in 31% and 58% of the cases evaluated, respectively, whereas immunopositivity for the proapoptotic proteins Bax and Bak was found in 47% and 58% of the samples. p53 immunopositivity was detected in 61% of the samples. The expression of Bcl-2 and p53 and the expression of Mcl-1 and Bax showed a positive association (P= 0.02 and P= 0.06 respectively), whereas the expression of Bax was inversely related to p53 (P= 0.008). The expression of Bcl-2 had a negative influence on relapse-free survival in this population of primary resected NSCLC patients (P= 0.02). The expression of p53 and Bcl-2 was significantly associated with metastasis-free survival (P< 0.01). Only patients with p53-positive tumours developed metastases during the follow-up period. Our results establish the frequent expression of the Bcl-2 family proteins Bcl-2, Mcl-1, Bax and Bak in NSCLC. It can be expected that Bcl-2 family members have no straightforward impact on clinical outcome in this disease because their interactions in the regulation of apoptosis are complex.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Apolinario, R. M., van der Valk, P., de Jong, J., Deville, W., van Ark-Otte, J. & Dingemans, A. M. (1997). Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15: 2456–2466.
Betticher, D. C., Heighway, J., Hasleton, P. S., Altermatt, H. J., Ryder, W. D., Cerny, T. & Thatcher, N. (1996). Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73: 294–300.
Boring, C. C., Squires, T. S., Tong, T. & Montgomery, S. (1994). Cancer statistics, 1994. Ca Cancer J Clin 44: 7–26.
Borner, C. (1996). Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 271: 12695–12698.
Borner, M., Myers, C., Sartor, O., Sei, Y., Toko, T., Trepel, J. & Schneider, E. (1995). Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis and proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 55: 2122–2128.
Borner, M. M., Joncourt, F. & Hotz, M. A. (1997). Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Br J Cancer 76: 1448–1454.
Brambilla, E., Gazzeri, S., Moro, D., Caron d. e. Fromentel, C., Gouyer, V., Jacrot, M. & Brambilla, C. (1993). Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143: 199–210.
Brambilla, E., Negoescu, A., Gazzeri, S., Lantuejoul, S., Moro, D., Brambilla, C. & Coll, J. L. (1996). Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 149: 1941–1952.
Brousset, P., Benharroch, D., Krajewski, S., Laurent, G., Meggetto, F., Rigal, H. F., Gopas, J., Prinsloo, I., Pris, J. & Delsol, G. (1996). Frequent expression of the cell death-inducing gene Bax in Reed–Sternberg cells of Hodgkin’s disease. Blood 87: 2470–2475.
Chiba, I., Takahashi, T., Nau, M. M., D’Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S. & Koga, H. (1990). Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 5: 1603–1610.
Eerola, A. K., Tormanen, U., Rainio, P., Sormunen, R., Bloigu, R., Vahakangas, K., Lehto, V. P., Soini, Y. & Paakko, P. (1997). Apoptosis in operated small cell lung carcinoma is inversely related to tumour necrosis and p53 immunoreactivity. J Pathol 181: 172–177.
Fisher, D. (1994). Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539–542.
Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Angeletti, C. A., Basolo, F. & Bevilacqua, G. (1995). Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71: 1003–1007.
Fujino, M., Dosaka, A. H., Harada, M., Hiroumi, H., Kinoshita, I., Akie, K. & Kawakami, Y. (1995). Prognostic significance of p53 and ras p21 expression in non-small cell lung cancer. Cancer 76: 2457–2463.
Harpole, D. J., Herndon 2nd, J., Wolfe, W. G., Iglehart, J. D. & Marks, J. R. (1995). A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55: 51–56.
Harris, C. C. (1996). Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442–1455.
Harris, C. C. & Hollstein, M. (1993). Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318–1327.
Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. (1991). p53 mutations in human cancers. Science 253: 49–53.
Jacobson, M. D., Weil, M. & Raff, M. C. (1997). Programmed cell death in animal development. Cell 88: 347–354.
Kaplan, E. L. & Meier, P. (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Kinzler, K. W. & Vogelstein, B. (1996). Life (and death) in a malignant tumour. Nature 379: 19–20.
Krajewska, M., Fenoglio, P. C., Krajewski, S., Song, K., Macdonald, J. S., Stemmerman, G. & Reed, J. C. (1996). Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 149: 1449–1457.
Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S. & Reed, J. C. (1996). Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567–1576.
Krajewski, S., Krajewska, M., Shabaik, A., Miyashita, T., Wang, H. G. & Reed, J. C. (1994). Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145: 1323–1336.
Krajewski, S., Bodrug, S., Krajewska, M., Shabaik, A., Gascoyne, R., Berean, K. & Reed, J. C. (1995). Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 146: 1309–1319.
Krajewski, S., Krajewska, M. & Reed, J. C. (1996). Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 56: 2849–2855.
Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., Hittelman, W. N. & Hong, W. K. (1995). Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 13: 1893–1903.
Liloglou, T., Ross, H., Prime, W., Donnelly, R. J., Spandidos, D. A., Gosney, J. R. & Field, J. K. (1997). p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. Br J Cancer 75: 1119–1124.
Miyashita, T., Harigai, M., Hanada, M. & Reed, J. C. (1994). Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131–3135.
Pastorino, U., Andreola, S., Tagliabue, E., Pezzella, F., Incarbone, M., Sozzi, G., Buyse, M., Menard, S., Pierotti, M. & Rilke, F. (1997). Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15: 2858–2865.
Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C. & Mason, D. Y. (1993). bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690–694.
Potten, C. (1996). What is an apoptotic index measuring? A commentary. Br J Cancer 74: 1743–1748.
Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E. & Doshi, H. M. (1992). Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828–4831.
Reed, J. C. (1997). Double identity for proteins of the Bcl-2 family. Nature 387: 773–776.
Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di, F. G., Rilke, F. & Veronesi, U. (1994). The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499–504.
Tormanen, U., Eerola, A. K., Rainio, P., Vahakangas, K., Soini, Y., Sormunen, R., Bloigu, R., Lehto, V. P. & Paakko, P. (1995). Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 55: 5595–5602.
UICC American Joint Committee on Cancer (1987). Manual for Staging of Cancer, 3rd edn. JB Lippincott: Philadelphia
WHO (1981). Histological Typing of Lung Tumours, 2nd edn. World Health Organization: Geneva
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Borner, M., Brousset, P., Pfanner-Meyer, B. et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 79, 952–958 (1999). https://doi.org/10.1038/sj.bjc.6690152
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690152
Keywords
This article is cited by
-
Chemical and Biological Insights on Phaulopsis falcisepala: A Source of Bioactive Compounds with Multifunctional Anticancer Potentials
Chemistry Africa (2023)
-
Himalayan flora: targeting various molecular pathways in lung cancer
Medical Oncology (2023)
-
The inhibitory role of stigmasterol on tumor growth by inducing apoptosis in Balb/c mouse with spontaneous breast tumor (SMMT)
BMC Pharmacology and Toxicology (2022)
-
FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation
Cancer Gene Therapy (2017)
-
Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer
Journal of Cancer Research and Clinical Oncology (2017)